Skip to content
2000
Volume 14, Issue 8
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

Background: Depressive disorders are among four leading causes of burden among the most disabling medical illnesses and antidepressant drugs (AD) occupying leading positions in the worldwide pharmaceutical market. However, typical AD show prolonged delay, refractory and adverse side effects. Methodology: The review analyzes experimental data and theoretical models of possible antidepressant effect of benzopentathiepine, 8-(trifluoromethyl)-1,2,3,4,5 - benzopentathiepin-6- amine hydrochloride (TC-2153). The antidepressant effect of TC-2153 is based on its ability to inhibit striatal enriched protein tyrosine phosphatase (STEP)- an enzyme that plays a key role in the intraneuronal transduction of signals from receptors of classic neurotransmitters and the brain derived neurotrophic factor (BDNF). The mechanism underlying antidepressant effect of TC-2153 includes increase in production as well as intracellular effect of BDNF on neuronal survival and neurogenesis. Results and Conclusion: There is no visible mechanisms of delay, refractory and adverse side effects of TC-2153. Thus, TC-2153 is a promising drug of new generation of atypical AD.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180814666161121112417
2017-08-01
2025-01-12
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180814666161121112417
Loading

  • Article Type:
    Research Article
Keyword(s): Antidepressant; BDNF; depression; serotonin; STEP; TC-2153
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test